Sanofi Genzyme Announces Recipients of 2016 Patient Advocacy Leadership (PAL) Awards
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sanofi Genzyme, the specialty care global business unit of Sanofi, today announced the recipients of the sixth annual Patient Advocacy Leadership (PAL) Awards. The global PAL Awards program supports projects by non-profit organizations that serve patients living with lysosomal storage disorders (LSDs), a group of rare, inherited disorders that can cause progressive and debilitating health problems.
Recipients were chosen by a review committee, composed of Sanofi Genzyme and outside experts, from among 27 proposals submitted by organizations from 15 different countries. Collaboration is a key component of the program, and grants were awarded to initiatives that involve two or more organizations working together to support the LSD community. This year, application guides and proposal forms were made available in five different languages, English, Spanish, Portuguese, Chinese and French.
“It’s important that these awards are accessible to non-profits around the world,” said Sanofi Genzyme’s Head of Global Rare Diseases, Richard Peters, MD, Ph.D. “This year, organizations were encouraged to apply in their own language, and we were thrilled to see 16 organizations submit applications in their native language.”
Since 2011, through the PAL Awards program, Sanofi Genzyme has recognized 46 organizations around the world supporting disease awareness, community mobilization, non-profit development and good governance activities. The PAL Awards program supplements Sanofi Genzyme’s charitable giving and does not replace the contributions made each year to support advocacy groups. The program is continuously reviewed and modified in an effort to best meet the needs of the global LSD community. More information on the PAL Awards program can be found at: www.PALAwards.com.
Sanofi Genzyme is pleased to announce the following 2016 PAL Award recipients:
Polish Association of Families Affected by Gaucher Disease, Polish
Association of Families Affected by Fabry Disease, and Polish Pompe
The Polish Association of Families Affected by Gaucher Disease, the Polish Association of Families Affected by Fabry Disease and the Polish Pompe Association are joining forces to create an online platform called “Storage” that provides comprehensive education about lysosomal storage disorders and an interactive forum for patients to connect with one another. As the project progresses, the platform will be used to gather and assess the needs of the LSD community to further inform Poland’s patient organizations’ programs and initiatives.
Croatian Alliance for Rare Diseases and National Organization for
Rare Disease of Serbia (Croatia)
A rare disease patient’s diagnostic journey is often long, complex and filled with misdiagnoses. Aimed at reducing the length of time to diagnosis, the Croatian Alliance for Rare Diseases and the National Organization for Rare Disease of Serbia are collaborating on a project called “Little Big Signs of Diagnosis,” an educational online platform for medical students. The platform will include videos of patients and their caregivers describing the first and most important symptoms of their disease, in an effort to raise awareness among medical students and better prepare them to correctly diagnosis LSDs in the future.
Rare Genomics Institute and Organization for Rare Disease India
(United States and India)
The genes that cause many LSDs have been identified, often making genetic sequencing a useful diagnostic tool. However, in order for genetic sequencing to be performed, patient advocate associates, who help patients navigate the process, must be properly trained, and patients and their caregivers must be properly informed. In an effort to strengthen and optimize genetic sequencing support functions, the Rare Genomics Institute in the United States and the Organization for Rare Disease India are working together to create training modules and educational resources for patient advocate associates, patients, caregivers and physicians.
Vietnam Rare Disease Network and the Vietnam National Hospital of
Increasing knowledge and reducing stigma around rare diseases are two big challenges for advocacy organizations. To address both issues, the Vietnam Rare Disease Network, in collaboration with the Vietnam National Hospital of Pediatrics, is publishing a book to provide disease information about specific LSDs, as well as share the stories of 22 rare disease patients and their families. It will be the first rare disease awareness book in Vietnam and can also serve as a reference manual for healthcare students.
The Association for Glycogen Storage Disease and Royal College of
General Practitioners (UK)
For many rare disease patients, their diagnostic odysseys often begin with a general practitioner who does not recognize diagnostic symptoms or refer them to the appropriate specialist. The Association for Glycogen Storage Disease is working with the Royal College of General Practitioners to educate general practitioners in the UK on the early signs and symptoms of Pompe disease and other glycogen storage diseases. They are developing concise visual e-learning modules to be featured on the website of the Royal College of General Practitioners, an organization with more than 52,000 general practitioner members.
Associação Catarinense de Pacientes e Amigos de Gaucher and
Associação Gaúcha de Fabry (Brazil)
Many health professionals are not specifically trained on how to care for patients living with rare and chronic health issues. To address this knowledge gap in Brazil, the Associação Catarinense de Pacientes e Amigos de Gaucher and the Associação Gaúcha de Fabry are collaborating to provide informational materials and trainings at community health centers, targeting doctors, nurses, receptionists, psychologists, and social workers. The trainings aim to help healthcare professionals identify rare disease patients early in their visit to a health center, so they can offer personalized care that addresses the particular needs of their disease and reduces the risk of inappropriate procedures.
About Lysosomal Storage Disorders
Lysosomal storage disorders (LSDs) are a group of more than 40 diseases. Each is caused by a genetic mutation that results in the deficiency or malfunction of a particular enzyme needed to remove waste material from cells. These waste molecules then accumulate, or build up, in cell lysosomes (smaller compartments within cells), disrupting cell function and causing a variety of symptoms. LSDs can be progressive, life-threatening and severely debilitating. Because these disorders are extremely rare, it can be difficult to find information about them. In the case of the most common of these disorders, Gaucher disease, it is estimated that only 10,000 people have been diagnosed worldwide. It is thought that many more people are affected by rare diseases than have been diagnosed. This is why access to information about LSDs is so important.
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Merial.
Sanofi Genzyme focuses on developing specialty treatments for debilitating diseases that are often difficult to diagnose and treat, providing hope to patients and their families.
Genzyme® is a registered trademark of Genzyme Corporation. Sanofi® is a registered trademark of Sanofi. All rights reserved.
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic conditions, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2015. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.